NasdaqGM:GPCRPharmaceuticals
Assessing Structure Therapeutics (GPCR) Valuation After Wider Quarterly Loss And Sharp Recent Share Price Pullback
Structure Therapeutics (GPCR) drew fresh attention after reporting first quarter results for the period ended March 31, 2026, with a net loss of US$75.97 million compared with US$46.83 million a year earlier.
See our latest analysis for Structure Therapeutics.
The first quarter update and wider clinical pipeline work have come against a backdrop of a share price that is down 23.5% over the past month and 45.9% year to date, while the 1 year total shareholder return of 52.7% and 3 year total...